IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorComputer and Technology
Phone650-940-4700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$42.60 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/3/2020 (Estimated)
OptionableNot Optionable
IRIDEX (NASDAQ:IRIX) Frequently Asked Questions
What is IRIDEX's stock symbol?
IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."
How were IRIDEX's earnings last quarter?
IRIDEX Co. (NASDAQ:IRIX) announced its quarterly earnings results on Thursday, November, 7th. The medical equipment provider reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.05. The medical equipment provider had revenue of $10.66 million for the quarter, compared to analyst estimates of $10.08 million. IRIDEX had a negative return on equity of 36.52% and a negative net margin of 23.42%. View IRIDEX's Earnings History.
When is IRIDEX's next earnings date?
What price target have analysts set for IRIX?
2 brokerages have issued twelve-month target prices for IRIDEX's stock. Their forecasts range from $7.00 to $7.00. On average, they expect IRIDEX's stock price to reach $7.00 in the next year. This suggests a possible upside of 266.5% from the stock's current price. View Analyst Price Targets for IRIDEX.
What is the consensus analysts' recommendation for IRIDEX?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRIDEX in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IRIDEX.
Has IRIDEX been receiving favorable news coverage?
Headlines about IRIX stock have been trending positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IRIDEX earned a news sentiment score of 2.3 on InfoTrie's scale. They also assigned news coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for IRIDEX.
Are investors shorting IRIDEX?
IRIDEX saw a decrease in short interest in October. As of October 31st, there was short interest totalling 77,700 shares, a decrease of 93.8% from the September 30th total of 1,250,000 shares. Based on an average daily volume of 95,000 shares, the short-interest ratio is currently 0.8 days. Approximately 0.7% of the shares of the company are sold short. View IRIDEX's Current Options Chain.
Who are some of IRIDEX's key competitors?
Some companies that are related to IRIDEX include Second Sight Medical Products (EYES), Fc Global Realty (FCRE), Soleno Therapeutics (SLNO), electroCore (ECOR), Precision Optics (PEYE), Helius Medical Technologies (HSDT), Reshape Lifesciences (RSLS), ENDRA Life Sciences (NDRA), Digirad (DRAD), Non-Invasive Monitoring Systems (NIMU), Viveve Medical (VIVE), Vaso (VASO), Nexeon Medsystems (NXNN), CHF Solutions (CHFS) and Escalon Medical (ESMC).
What other stocks do shareholders of IRIDEX own?
Who are IRIDEX's key executives?
IRIDEX's management team includes the folowing people:
- Mr. William M. Moore, Chairman of Directors, Pres & CEO (Age 70)
- Dr. George R. Marcellino, VP of Clinical Affairs (Age 70)
- Mr. Romeo R. Dizon, VP of Fin.
- Ms. Leigh Salvo, Head of Investor Relations
- Mr. Timothy D. Buckley, VP of Marketing & North American Sales (Age 44)
Who are IRIDEX's major shareholders?
IRIDEX's stock is owned by many different of retail and institutional investors. Top institutional investors include Eidelman Virant Capital (0.86%), Perkins Capital Management Inc. (0.32%), Osborne Partners Capital Management LLC (0.19%) and Gabelli Funds LLC (0.15%). Company insiders that own IRIDEX stock include Associates & Paragon A Paragon, Robert Earle Grove, Romeo R Dizon, Scott Shuda and William M Moore. View Institutional Ownership Trends for IRIDEX.
Which major investors are selling IRIDEX stock?
IRIX stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Eidelman Virant Capital and Osborne Partners Capital Management LLC. View Insider Buying and Selling for IRIDEX.
Which major investors are buying IRIDEX stock?
IRIX stock was purchased by a variety of institutional investors in the last quarter, including Gabelli Funds LLC. Company insiders that have bought IRIDEX stock in the last two years include Associates & Paragon A Paragon, Robert Earle Grove, Scott Shuda and William M Moore. View Insider Buying and Selling for IRIDEX.
How do I buy shares of IRIDEX?
Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is IRIDEX's stock price today?
One share of IRIX stock can currently be purchased for approximately $1.91.
How big of a company is IRIDEX?
IRIDEX has a market capitalization of $26.32 million and generates $42.60 million in revenue each year. The medical equipment provider earns $-12,810,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. View Additional Information About IRIDEX.
What is IRIDEX's official website?
How can I contact IRIDEX?
IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider can be reached via phone at 650-940-4700 or via email at [email protected]
MarketBeat Community Rating for IRIDEX (NASDAQ IRIX)
MarketBeat's community ratings are surveys of what our community members think about IRIDEX and other stocks. Vote "Outperform" if you believe IRIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
